New hope for stomach cancer patients who failed immunotherapy
NCT ID NCT07311408
First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 28 times
Summary
This study tests a combination of two or three drugs (SHR-1701, rivoceranib, and possibly SHR-2554) in 40 adults with advanced stomach or gastroesophageal junction cancer that has worsened after or was not tolerated during first-line immunotherapy. The goal is to see if the combination can shrink tumors or slow cancer growth. Participants must have HER2-negative cancer and provide tumor samples for analysis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Liaoning Provincial Cancer Hospital
RECRUITINGShenyang, Liaoning, 11000, China
Conditions
Explore the condition pages connected to this study.